If ANYTHING EXISTS LIKE THIS IN STROKE, I DON'T SEE IT. And until we get survivors in charge, NOTHING WILL OCCUR.
Last year, backed by dedicated donors like you, The Michael J. Fox Foundation (MJFF) awarded $75 million in 231 grants to projects designed to translate promising research into real solutions for people living with Parkinson’s.
In 2021, we are determined to keep the momentum going by
funding even more research to advance the next life-changing
breakthrough. Please consider renewing your investment in MJFF’s 2021 vision by donating today. |
|
Patients’
greatest need remains a therapy to slow or stop progression of the
disease. To meet that need, we are building a diversified portfolio of
targets and treatments that gives us more shots on goal toward more wins
for the Parkinson’s community. Here’s a snapshot of what’s in the pipeline: |
|
|
Today, more than 20 approaches focused on three key
genetic targets — alpha-synuclein, LRRK2 and GBA — have entered human
trials, with many more in pre-clinical development. | |
|
|
Five treatments are currently in human trials for
inflammation, which impacts neurodegenerative diseases and has ties to
genetic factors and the environment. | |
|
|
Studies of approved treatments with the potential to be repurposed for Parkinson’s continue, including one MJFF-funded project investigating a drug for enlarged prostate after it was linked to lower PD risk. | | | | |
Every project serves a unique purpose as we work quickly
to gather more insight into the disease and illuminate pathways to
stop, slow and ultimately end Parkinson
’s for good. Your donation ensures no stone is left unturned.
No comments:
Post a Comment